Gain Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Gain Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Gain Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$4.46M, a 8.72% increase year-over-year.
  • Gain Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$21.4M, a 4.38% increase year-over-year.
  • Gain Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$22.3M, a 25.2% decline from 2022.
  • Gain Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$17.8M, a 28.6% decline from 2021.
  • Gain Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$13.8M, a 297% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$22.3M -$4.48M -25.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-26
2022 -$17.8M -$3.95M -28.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-26
2021 -$13.8M -$10.3M -297% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$3.48M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.